For emergency monovalent vaccine programmes directed against swine foot-and-mouth disease serotype O, the inactivated antigen API is most commonly formulated into a sterile aqueous injection using a defined dilution-to-potency approach. The received antigen concentrate is first normalized against a reference serology established by sucrose density gradient centrifugation at 200,000 × g for 18 hours, with the intact 146S peak collected and quantified by UV absorbance at 260 nm using a batch-specific extinction coefficient derived from the reference antigen. The normalized bulk is then blended in a stainless steel jacketed vessel with a circulation-controlled heating/cooling system at 4 °C ± 1 °C, using a low-shear axial-flow agitator at 50–80 rpm for 30 minutes to avoid shear-induced aggregation of antigen particles that occurs above 300 s⁻¹. The formulation buffer for the aqueous injection consists of 0.04 M phosphate buffer pH 7.6, 0.5% (w/v) lactalbumin hydrolysate, 2% (w/v) sucrose, and 0.01% (w/v) thiomersal as preservative; osmolality is adjusted to 280–320 mOsm/kg with sodium chloride. The final dose volume of 2.0 mL is targeted to contain at least 6 PD50 per dose of the Type O strain, as recommended for emergency vaccination in the World Organisation for Animal Health Terrestrial Manual Chapter 3.1.8 under the section on vaccine potency. Sterile filtration is performed through a sequential 0.45 µm polyethersulfone prefilter and a 0.22 µm polyvinylidene fluoride membrane under aseptic conditions, with filter integrity tested before and after filling by bubble point according to ASTM F838-20. Production-scale failures observed on multi-dose vial filling lines include antigen loss of up to 12–15% when silicone tubing peristaltic pumps are operated above 25 rpm due to adsorption to tubing surfaces; therefore, positive displacement rotary piston pumps with ceramic heads are preferred. The finished product is filled into 20 mL 50-dose or 100 mL 250-dose HDPE vials with chlorobutyl rubber stoppers and aluminum flip-off seals, stored at 2–8 °C, and assigned a shelf life of 24 months. Each batch must pass sterility testing per Ph. Eur. 2.6.1, an endotoxin limit of ≤ 0.5 EU/mL per Ph. Eur. 2.6.14, and a safety test for residual live FMDV using three passages in BHK-21 cell monolayers per OIE Chapter 3.1.8. The aqueous formulation has a lower viscosity than oil-adjuvanted forms, typically 1.2–2.5 cP at 25 °C, which makes it suitable for rapid syringe or automatic injector delivery in mass vaccination campaigns.

What Process Window Prevents Premature Phase Inversion in Water-In-Oil-In-Water FMD Vaccines?

Because the aqueous antigen bulk serves as the discontinuous phase in a water-in-oil-in-water (W/O/W) system, the shear history before emulsification determines both antigen integrity and long-term physical stability of the emulsion. The aqueous phase is prepared by blending the Type O antigen concentrate with phosphate buffer pH 7.4 to a final aqueous volume fraction of 50% w/w, then transferred to a high-shear rotor-stator mixer fitted with a 0.5 mm radial gap, such as the Silverson L5T or IKA DR 2000/20 line. The oil phase is Montanide ISA 206, a mineral oil-based ready-to-use adjuvant supplied by Seppic, pre-warmed to 30 °C ± 1 °C to reduce viscosity below 80 cP before mixing. The aqueous phase is slowly introduced into the oil phase under continuous shear at 6000–8000 rpm for 5–10 minutes to form a primary emulsion, after which a second aqueous stabilising phase containing 0.1% (w/v) Tween 80 is added under reduced shear at 1000–1500 rpm for 3 minutes. Premature phase inversion and phase separation occur when the aqueous fraction exceeds 55% w/w or when the emulsification temperature exceeds 35 °C, resulting in viscosity above 120 cP and droplet size distribution wider than 1.5–8.0 µm; these are observable batch-to-batch failure modes in commercial mixing vessels when temperature probes are not recalibrated after steam sterilization cycles. The finished W/O/W emulsion has a target mean droplet diameter D50 of 2.0–3.5 µm measured by laser diffraction per ISO 13320:2020, and a Brookfield viscosity of 45–120 cP at 25 °C using spindle 2 at 12 rpm per ISO 2555:2018. Antigen recovery from the emulsion for quality control is performed by breaking a 5 mL sample with 10% (v/v) Triton X-100 and isooctane, followed by sucrose density gradient quantitation; recovery outside 80–100% of the pre-emulsion 146S content indicates shear damage and requires batch rework. The final dose volume is 2.0 mL containing 6 PD50 of Type O antigen. The emulsion is filled into 50 mL and 100 mL LDPE or PETG bottles with polypropylene caps and stored at 2–8 °C; physical stability is assessed by accelerated storage for 6 months at 25 °C with no creaming exceeding 5% phase volume and no change in droplet size distribution. Compliance with OIE Chapter 3.1.8 and Ph. Eur. monograph 0063 requires intramuscular injection in the neck of pigs, with a booster at 21–28 days for primo-vaccinated animals and revaccination every 4–6 months in endemic regions. The terminal product must not be mixed with aqueous diluents in the field until the point of use because dilution of the W/O/W matrix below the critical oil volume fraction breaks the emulsion.

Lyophilized Antigen Cake and the Glass Transition Constraints for Stockpile Stability

A lyophilized antigen cake for strategic vaccine bank reserves is produced from the concentrated Type O antigen bulk blended with a cryoprotectant matrix of 5% (w/v) sucrose, 1% (w/v) sorbitol, and 0.5% (w/v) lactalbumin hydrolysate in 0.02 M phosphate buffer pH 7.6. The formulated liquid is filled into 5 mL Type I borosilicate glass vials at 2.5 mL per vial, with a fill line leaving sufficient headspace to avoid product bumping during primary drying. Lyophilization is performed in a Tofflon Lyomaster 50 or equivalent freeze dryer with shelf temperature programming from -50 °C ± 2 °C to 20 °C over a 34-hour cycle, with primary drying at a shelf temperature of -20 °C ± 2 °C and chamber pressure of 0.200 mbar, followed by secondary drying at 30 °C ± 1 °C for 6 hours. The critical formulation parameter is the glass transition temperature of the maximally frozen concentrate, Tg', which is -32 °C ± 2 °C for this matrix; shelf temperature excursions above -30 °C during primary drying cause collapse of the cake, as detected by a rise in product resistance from 0.5 cm²·Torr·h/g to above 2.0 cm²·Torr·h/g on the Pirani gauge versus capacitance manometer pressure differential. Residual moisture is determined by Karl Fischer titration per Ph. Eur. 2.5.12 after stopper closure under vacuum, with a release specification of ≤ 2.0%; residual moisture above 3.0% shifts the anhydrous cake glass transition from 45 °C ± 3 °C to below 25 °C, reducing long-term stability and allowing antigen denaturation. The cake is an off-white, smooth solid with a specific surface area of 0.8–1.5 m²/g, determined by nitrogen adsorption per ISO 9277:2010. Reconstitution with 2.0 mL water for injection restores a translucent liquid with a pH of 7.5–7.8, osmolality 270–320 mOsm/kg, and no visible particulates when examined per Ph. Eur. 2.9.20. The antigen content after reconstitution must retain at least 90% of the pre-lyophilization 146S value, determined by sucrose density gradient; losses of 10–20% are common when the freezing rate is too slow, such as shelf cooling at 0.5 °C/min instead of 1.0 °C/min, due to ice crystal growth and surface denaturation. Terminal storage is at -20 °C ± 5 °C for 5 years, with an intermediate stability of 12 months at 2–8 °C; repeated freeze-thaw cycles beyond 3 result in a drop in 146S recovery below 70%, a boundary that must be communicated to national vaccine bank managers. This route avoids the need for continuous cold-chain liquid storage and is used in antigen reserve programmes where the bulk antigen is stored for years before compounding into emergency aqueous or emulsion vaccines.

When Multivalent Type O/A/Asia 1 Blends Are Compounded, Antigen Mass Ratios Require Rebalancing

When multivalent vaccines are prepared from a Type O antigen API combined with Type A and Asia 1 antigen concentrates, the antigen payload per dose must be adjusted for serotype-specific interference in the host immune response. Each monovalent bulk batch is separately quantified for intact 146S particles by sucrose density gradient centrifugation or by a double-antibody sandwich ELISA calibrated against a reference antigen with a known 146S concentration, and the Type O component is then blended at a mass ratio that yields at least 6 PD50 per 2.0 mL dose in the final multivalent product. Empirical batch records from production-scale antigen banks indicate that Type O antigen often requires 1.5–2.0-fold higher 146S payload in trivalent formulations than in monovalent aqueous formulations to maintain the same seroneutralizing antibody titre at 21 days post-vaccination; this is attributed to antigenic competition and the different adjuvant binding affinities of capsid surface charge. The blending process is conducted in a 500 L stainless steel jacketed vessel at 4 °C ± 1 °C under a nitrogen overlay, with a low-shear axial-flow impeller at 60–90 rpm for 45 minutes. The buffer system for the blended aqueous intermediate is 0.02 M HEPES pH 7.4 with 0.5% (w/v) lactalbumin hydrolysate, 2% (w/v) sucrose, and 0.01% (w/v) thiomersal; for the oil-adjuvanted version, the blended aqueous phase is then emulsified with Montanide ISA 206 or ISA 201 under the process window described for monovalent emulsions. The terminal product is filled into 20-dose or 50-dose PETG bottles and released according to OIE Chapter 3.1.8 and Ph. Eur. monograph 0063, with a potency test using a two-dose vaccination schedule in pigs, followed by challenge with virulent homologous strains at 28 days; the product must demonstrate protection in at least 12 of 16 animals, depending on the national regulatory protocol. The multivalent vaccine is indicated for prophylactic vaccination in pigs in regions where multiple FMD serotypes co-circulate; revaccination is required every 4 months in endemic areas, and stored product must be protected from freezing because ice crystal formation disrupts the emulsion and precipitates antigen from aqueous blends. Published data for specific trivalent swine formulations is limited compared with cattle potency models, so a risk-based release using serological non-inferiority against monovalent batches is applied when challenge facilities are unavailable.

The release and stability matrix for the two principal injectable forms is consolidated in the following table.

For needle-free intradermal delivery platforms used in commercial swine herds, the Type O inactivated antigen API is formulated as a low-viscosity aqueous solution intended for 0.2 mL intradermal injection per dose. The formulation is prepared by diluting the antigen concentrate with a buffer containing 0.02 M phosphate pH 7.6, 1% (w/v) sorbitol, and 0.25% (w/v) sodium chloride to achieve an osmolality of 280–320 mOsm/kg and a viscosity below 5 cP at 25 °C, which is the maximum recommended by needle-free injector manufacturers for reliable dosing through micro-orifice arrays. The diluted solution is sterile filtered through a 0.22 µm PVDF membrane and filled into single-use 0.2 mL cartridge bodies made of cyclic olefin copolymer, using a peristaltic filling line equipped with in-process check-weighing at 100% of units; fill volume tolerance is ± 0.01 mL. Each 0.2 mL dose contains at least 6 PD50 of Type O antigen, based on the same potency reference as the 2.0 mL intramuscular dose; the dose reduction is supported by the high density of antigen-presenting cells in the dermis and by the needle-free delivery device's ability to disperse antigen into the dermal layer at a pressure of 850–1100 psi. The needle-free injector used for pigs is typically a gas-powered or spring-powered device with a nozzle diameter of 0.12–0.25 mm; maintenance of the nozzle orifice is critical because a 15% reduction in orifice diameter from protein film build-up causes jet formation failure and visible wetting on the skin surface. Compliance with OIE Chapter 3.1.8 and Ph. Eur. 0063 for the aqueous injection applies to the intradermal formulation only if the national regulatory authority accepts the modified route; in some jurisdictions, full potency demonstration in pigs by challenge at 28 days post-vaccination is required before field approval. The finished intradermal solution is stored at 2–8 °C and must be protected from light to avoid photo-oxidation of the antigen; in-use stability after cartridge removal from the cold chain is 4 hours at ambient temperature up to 25 °C. Terminal quality release includes sterility per Ph. Eur. 2.6.1, endotoxin ≤ 0.5 EU/mL per Ph. Eur. 2.6.14, and 146S recovery of at least 90% of the pre-filtration value.

Granular Premix Coating Stability Remains an Investigational Boundary, Not a Licensed Route

Granular premix delivery of inactivated foot-and-mouth disease antigen remains a research-stage formulation pathway, and no commercial oral FMD vaccine or premix is licensed under OIE Chapter 3.1.8 or Ph. Eur. 0063 as of the current compendial editions. Research-grade granules have been prepared by ionic gelation of sodium alginate at 2% (w/v) containing the antigen concentrate, followed by crosslinking in 0.5 M calcium chloride; the resulting beads are then coated with 0.5% (w/v) chitosan in 0.1 M acetate buffer pH 5.5 to reduce gastric acid degradation. Encapsulation efficiency determined by extraction and 146S quantitation is 70–80%, but the pH-labile capsid remains susceptible to denaturation at gastric pH 3.0 and proteolytic cleavage by pepsin; in vitro release studies in simulated gastric fluid per Ph. Eur. 2.9.3 show more than 60% antigen loss within 2 hours unless the beads are subsequently coated with a sustained-release lipid layer. A granulation step in a fluidised bed with inlet air at 30 °C and spray rate 5 mL/min is used to deposit the alginate-coating mixture onto microcrystalline cellulose spheres of 200–300 µm; the dried granules have a bulk density of 0.55–0.65 g/mL and angle of repose 25–35°, but no production-scale batch data are available. In swine, oral administration of these research granules at 10× the injectable antigen dose produced seroneutralization titres of 0.6–1.2 log10 after 28 days, below the protective threshold associated with parenteral vaccination; published data for this specific configuration is limited. The main operational boundary is the absence of mucosal adjuvants licensed for FMD oral delivery; without a mucoadhesive penetration enhancer, the antigen is not translocated across the intestinal epithelium efficiently. Tablets and capsules are similarly not used for this inactivated antigen API because tableting pressures above 50 MPa generate shear and heat that denature the capsid, and capsule filling does not protect the antigen from gastrointestinal degradation. Therefore, the granular premix, tablet, and capsule routes are excluded from commercial applications; only injectable aqueous, W/O/W emulsion, lyophilized cake, and needle-free intradermal liquid forms have regulatory or industrial acceptance.